Orchestrating networks in the biopharmaceutical industry: small hub firms can do it

References

• Arora , A and Gambardella , A . 1994a . The changing technology of technological change: general and abstract knowledge and the division of innovative labour . Research policy , 23 : 523 – 532 .
   Web of Science ®Google Scholar
• Arora , A and Gambardella , A . 1994b . Evaluating technological information and utilizing it . Journal of Economic Behavior & Organization , 24 : 91 – 114 .
   Web of Science ®Google Scholar
• Arthurs , JD and Busenitz , LW . 2006 . Dynamic capabilities and venture performance: the effects of venture capitalists . Journal of Business Venturing , 21 ( 2 ) : 195 – 215 .
   Web of Science ®Google Scholar
• Bamfield , P . 2003 . “ The structural components of an R&D organisation ” . In Research and development management in the chemical and pharmaceutical industry , 2nd , Wiley-VCH .
   Google Scholar
• Baum , JA , Calabrese , T and Silverman , BS . 2000 . Don't go it alone: alliance network composition and startups'performance in canadian biotechnology . Strategic Management Journal , 21 : 267 – 294 .
   Web of Science ®Google Scholar
• Bigras Y., 2002. How networked and virtual businesses are changing the way companies work together. CMA Management
   Google Scholar
• Brass , DJ and Burkhardt , ME . 1993 . Potential power and power use: An investigation of structure and behavior . Academy of Management Journal , 36 : 441 – 470 .
   Web of Science ®Google Scholar
• Chesbrough , HW and Schwartz , K . 2007 . Innovating business models with co-development partnerships . Research Technology Management , 50 ( 1 ) : 55 – 59 .
   Web of Science ®Google Scholar
• Chesbrough H.W. and Teece D.J., 1996. Organizing for innovation: when is virtual virtuous? Harvard Business Review
   Google Scholar
• Danzon , PM , Nicholson , S and Pereira , NS . 2005 . Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances . Journal of Health Economics , 24 : 317 – 339 .
   PubMed Web of Science ®Google Scholar
• Dhanaraj , C and Parkhe , A . 2006 . Orchestrating innovation networks . Academy of Management Review , 31 ( 3 ) : 659 – 669 .
   Web of Science ®Google Scholar
• DiMasi , J and Grabowski , HG . 2007 . The cost of biopharmaceutical R&D: is biotech different? . Managerial and Decision Economics , 28 : 469 – 479 .
   Google Scholar
• DiMasi , JA . 1991 . Cost of innovation in the pharmaceutical industry . Journal of Health Economics , 10 : 107 – 142 .
   PubMed Web of Science ®Google Scholar
• DiMasi , JA , Hansen , RW and Grabowski , HG . 2003 . The price of innovation: new estimates of drug development cost . Journal of Health Economics , 22 : 151 – 185 .
   PubMed Web of Science ®Google Scholar
• Durand , R , Bruyaka , O and Mangematin , V . 2008 . Do science and money go together? The case of the french biotech industry . Strategic Management Journal , 29 ( 12 ) : 1281 – 1299 .
   Web of Science ®Google Scholar
• Eisenhardt , K . 1989 . Building theories from case study research . Academy of Management Review , 14 ( 4 ) : 532 – 550 .
   Web of Science ®Google Scholar
• Fisken , J and Rutherford , J . 2002 . Business models and investment trends in the biotechnology industry in Europe . Journal of Commercial Biotechnology , 8 ( 3 ) : 191 – 199 .
   Google Scholar
• Gassmann , O and Reepmeyer , G . 2005 . Organizing pharmaceutical innovation: from Science-based knowledge creators to drug-oriented knowledge brokers . Creativity and Innovation Management , 14 ( 3 ) : 233 – 245 .
   Google Scholar
• Gassmann , O , Reepmeyer , G and von Zedtwitz , M . 2004 . “ Leading Pharmaceutical Innovation ” . In Trends and Drivers for Growth in the Pharmaceutical Industry , Berlin : Springer .
   Google Scholar
• Govindarajan , V and Gupta , AK . 2001 . Strategic innovation: a conceptual Road Map . Business Horizons , 44 ( 4 ) : 3 – 12 .
   Google Scholar
• Hoan , H and Rothaermel , FT . 2005 . The effect of general and partner-specific alliance experience on joint R&D project performance . Academy of Management Journal , 48 ( 2 ) : 332 – 345 .
   Web of Science ®Google Scholar
• Hopkins , MM . 2007 . The myth of biotech revolution: an assessment of technological, clinical and organisational change . Research policy , 36 ( 4 ) : 566 – 589 .
   Web of Science ®Google Scholar
• Howells , J , Gagliardi , D and Malik , K . 2008 . The growth and management of R&D outsourcing: evidence from UK pharmaceuticals . R&D Management , 38 ( 2 ) : 205 – 219 .
   Web of Science ®Google Scholar
• Lane , C and Probert , J . 2007 . The external sourcing of technological knowledge by US Pharmaceutical companies: strategic goals and inter-organizational relationships . Industry and Innovation , 14 ( 1 ) : 5 – 25 .
   Google Scholar
• Laroia , G and Krishnan , S . 2005 . Managing drug discovery alliances for success . Research Technology Management , 48 ( 5 ) : 42 – 50 .
   Web of Science ®Google Scholar
• Lee , YH . 2006 . Supply chain model for the semiconductor industry in consideration of manufacturing characteristics . Production Planning and Control , 17 ( 5 ) : 518 – 533 .
   Web of Science ®Google Scholar
• Liebeskind , JP . 1996 . Social networks, learning, and flexibility: sourcing scientific knowledge in new biotechnology firms . Organization Science , 7 ( 4 ) : 428 – 443 .
   Web of Science ®Google Scholar
• Lorenzoni , G and Baden-Fuller , C . 1995 . Creating a strategic center to manage a web of partners . California Management Review , 37 ( 3 ) : 146 – 163 .
   Web of Science ®Google Scholar
• Orsenigo , L . 1998 . The evolution of knowledge and the dynamics of industry network . Journal of Management and Governance , 1 : 147 – 175 .
   Google Scholar
• Osterwalder , A , Pigneur , Y and Tucci , CL . 2005 . Clarifying business models: origins, present, and future of the concept . Communications of the Association for Information Systems , 15 : 3 – 15 .
   Google Scholar
• Papadopoulos , S . 2000 . Business models in biotech. . Nature Biotechnology , 18(Supplement)
   Web of Science ®Google Scholar
• Papania , L . 2008 . Using brand personality to assess whether biotechnology firms are saying the right things to their network . Journal of Commercial Biotechnology , 14 ( 3 ) : 247 – 255 .
   Google Scholar
• Pettigrew , AM . 1990 . Longitudinal field research on change: theory and practice . Organization Science , 1 ( 3 ) : 267 – 292 .
   Web of Science ®Google Scholar
• Pisano , G . 1990 . The R&D boundaries of the firm: an empirical analysis . Administrative Science Quarterly , 35 : 153 – 176 .
   Web of Science ®Google Scholar
• Pisano , G . 2006 . Can science be a business? Lessons from Biotech . Harvard Business Review , 84 ( 10 ) : 114 – 125 .
   PubMed Web of Science ®Google Scholar
• Pisano , G , Shan , W and Teece , DJ . 1988 . “ Joint ventures and collaboration in the biotechnology industry ” . In International collaborative ventures in US manufacturing , Edited by: Mowery , D . 183 – 222 . Cambridge : Ballinger .
   Google Scholar
• Powell , WW . 1990 . Neither market nor hierarchy: network forms of organisation . Research in Organizational Behavior , 12 : 295 – 336 .
   Web of Science ®Google Scholar
• Powell , WW . 1998 . Learning from collaboration: knowledge and networks in the biotechnology and pharmaceutical industries . California Management Review , 40 ( 3 ) : 228 – 240 .
   Web of Science ®Google Scholar
• Powell , WW , Koput , KW and Smith-Doerr , L . 1996 . Interorganizational collaboration and the locus of innovation. Networks of learning in biotechnology . Administrative Science Quarterly , 41 : 116 – 145 .
   Web of Science ®Google Scholar
• Prencipe , A and Tell , F . 2001 . Interproject learning: processes and outcomes of knowledge codification in project-based firms . Research Policy , 30 ( 9 ) : 1373 – 1394 .
   Web of Science ®Google Scholar
• Rothaermel , FT . 2001 . Incumbent's advantage through exploiting complementary assets via interfirm cooperation . Strategic Management Journal , 22 : 687 – 699 .
   Web of Science ®Google Scholar
• Rothman , H and Kraft , A . 2006 . Downstream and into deep biology: evolving business models in ‘top tier’ genomics companies . Journal of Commercial Biotechnology , 12 ( 2 ) : 86 – 98 .
   Google Scholar
• Rugman , A and D'Cruz , J . 1997 . The theory of the flagship firm . European Management Journal , 15 ( 4 ) : 403 – 412 .
   Google Scholar
• V. Sabatier, Rousselle, T., and Mangematin, V., 2008. Going virtual in the European biopharmaceutical industry: conductors and oxpeckers make it. 9th working conference on virtual enterprises, Poznan, Poland, Springer
   Google Scholar
• Sawhney , M and Parikh , D . 2001 . Where values lives in a networked world . Harvard Business Review , : 76 – 86 .
   Web of Science ®Google Scholar
• Scarbrough , H . 2004 . Project-based learning and the role of learning boundaries . Organization Studies , 25 ( 9 ) : 1579 – 1600 .
   Web of Science ®Google Scholar
• Shan , W , Walker , G and Kogut , B . 1994 . Interfirm cooperation and startup innovation in the biotechnology industry . Strategic Management Journal , 15 ( 5 ) : 387 – 394 .
   Web of Science ®Google Scholar
• Siggelkow , N . 2007 . Persuasion with case studies . Academy of Management Journal , 50 ( 1 ) : 20 – 24 .
   Web of Science ®Google Scholar
• Teece , DJ . 1986 . Profiting from technological innovation: implications for integration, collaboration, licensing and public policy . Research Policy , 15 : 285 – 305 .
   Web of Science ®Google Scholar
• Teece , DJ . 2000 . Managing intellectual capital: Organizational, strategic, and policy dimensions , London : Oxford University Press .
   Google Scholar
• Wasserman , S and Galaskiewicz , J . 1994 . Advances in social network analysis , London : Sage .
   Google Scholar
• Weisenfeld , U , Reeves , JC and Hunck-Meiswinkel , A . 2001 . Technology management and collaboration profile: virtual companies and industrial platforms in the high-tech biotechnology industries . R&D Management , 31 ( 1 ) : 91 – 100 .
   Web of Science ®Google Scholar
• Zhang , J , Baden-Fuller , C and Mangematin , V . 2007 . Technological knowledge base, R&D organization structure and alliance formation: evidence from the biopharmaceutical industry . Research Policy , 36 : 515 – 528 .
   Web of Science ®Google Scholar